Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Aethlon Medical, Inc. (AEMD : NSDQ)

• Company Description    Aethlon Medical, Inc. is a development stage medical device company focused on expanding the applications of our Hemopurifier (R) platform technology, which is designed to rapidly reduce the presence of infectious viruses and other toxins from human blood. In this regard, its core focus is the development of therapeutic devices that treat acute viral conditions, chronic viral diseases and pathogens targeted as potential biological warfare agents. The Hemopurifier(R) combines the established scientific principles of affinity chromatography and hemodialysis as a means to mimic the immune system's response of clearing viruses and toxins from the blood before cell and organ infection can occur. The Hemopurifier(R) cannot cure viral conditions but can prevent virus and toxins from infecting unaffected tissues and cells. The company has completed pre-clinical blood testing of the Hemopurifier(R) to treat HIV and Hepatitis-C, and have completed human safety trials on Hepatitis-C infected patients in India. Number of Employees: 9

• Price / Volume Information    Yesterday's Closing Price: $1.24 Daily Weekly Monthly 20 Day Moving Average: 289,231 shares Shares Outstanding: 2.59 (millions) Market Capitalization: $3.21 (millions) Beta: 1.69 52 Week High: $8.44 52 Week Low: $1.10 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -54.07% -56.56% 12 Week -54.41% -61.75% Year To Date -81.98% -83.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 11555 SORRENTO VALLEY ROAD SUITE 203 - SAN DIEGO,CA 92121 USA ph: 619-941-0360 fax: - susan@sanoonan.com http://www.aethlonmedical.com

• General Corporate Information    Officers James B. Frakes - Chief Executive Officer and Chief Financial Office Edward G. Broenniman - Chairman Chetan S. Shah - Director Angela Rossetti - Director Nicolas Gikakis - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-HMO Sector: Medical CUSIP: 00808Y505 SIC: 3841 Fiscal Year Fiscal Year End: March Last Reported Quarter: 12/01/24 Next Expected EPS Date: 08/13/25 Share - Related Items Shares Outstanding: 2.59 Most Recent Split Date: 6.00 (0.13:1) Beta: 1.69 Market Capitalization: $3.21 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.68 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-3.53 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/13/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.49 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 90.51% vs. Previous Quarter: 35.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -221.38 12/31/24 - -153.96 ROA 06/30/25 - - 03/31/25 - -156.83 12/31/24 - -109.13 Current Ratio 06/30/25 - - 03/31/25 - 3.13 12/31/24 - 2.80 Quick Ratio 06/30/25 - - 03/31/25 - 3.13 12/31/24 - 2.80 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 2.55 12/31/24 - 2.48 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©